Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data. J of Skin [Internet]. 2019 Mar. 11 [cited 2025 Apr. 20];3(2):169. Available from: https://skin.dermsquared.com/skin/article/view/526